IPCALAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.9
| Stock Code | IPCALAB | Market Cap | 39,173 Cr. | Current Price | 1,544 ₹ | High / Low | 1,679 ₹ |
| Stock P/E | 33.9 | Book Value | 315 ₹ | Dividend Yield | 0.26 % | ROCE | 20.0 % |
| ROE | 15.5 % | Face Value | 1.00 ₹ | DMA 50 | 1,558 ₹ | DMA 200 | 1,486 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 285 Cr. | PAT Prev Qtr | 303 Cr. |
| RSI | 44.2 | MACD | 1.18 | Volume | 1,29,599 | Avg Vol 1Wk | 1,30,362 |
| Low price | 1,252 ₹ | High price | 1,679 ₹ | PEG Ratio | 1.02 | Debt to equity | 0.04 |
| 52w Index | 68.2 % | Qtr Profit Var | 112 % | EPS | 44.6 ₹ | Industry PE | 32.1 |
Ipca Laboratories (IPCALAB) shows moderate potential for swing trading. The current price of ₹1,544 is slightly below the 50 DMA (₹1,558) but above the 200 DMA (₹1,486), reflecting mixed technical signals. RSI at 44.2 suggests the stock is approaching oversold territory, while MACD at 1.18 indicates mild bullish momentum. Fundamentals are decent with ROCE at 20.0% and ROE at 15.5%. EPS of ₹44.6 and a PEG ratio of 1.02 suggest fair valuation relative to growth. However, quarterly PAT declined from ₹303 Cr. to ₹285 Cr., showing mild earnings weakness. Low debt-to-equity (0.04) adds financial stability.
✅ Optimal Entry Price: Around ₹1,520–₹1,540 (near DMA support)
📈 Exit Strategy (if already holding): Consider exiting near ₹1,620–₹1,640 (resistance zone close to recent high).
---
🌟 Positive
- 📈 Strong [ROCE](ca://s?q=Explain_ROCE) of 20.0% and [ROE](ca://s?q=Explain_ROE) of 15.5% indicate efficient capital use.
- 📊 EPS of ₹44.6 supports profitability.
- 📉 Very low [debt-to-equity](ca://s?q=Debt_to_equity_ratio) ratio of 0.04 ensures financial stability.
- 📈 PEG ratio of 1.02 indicates fair valuation relative to growth.
⚠️ Limitation
- 📉 High P/E of 33.9 compared to industry PE of 32.1 suggests slight overvaluation.
- 📊 Dividend yield at 0.26% is modest.
- 📉 Quarterly PAT declined from ₹303 Cr. to ₹285 Cr., showing mild weakness.
- 📊 Trading volume (1.29 lakh) is slightly below weekly average (1.30 lakh), indicating weaker participation.
📰 Company Negative News
- 📉 Decline in quarterly profits.
- 📊 Lower trading activity compared to average volumes.
📢 Company Positive News
- 💡 Institutional investors (FII +0.01%, DII +0.14%) increased holdings.
- 📈 Stock trading near DMA levels, confirming potential support.
- 📊 PEG ratio of 1.02 indicates fair valuation relative to growth.
🏭 Industry
- 📊 Industry PE is 32.1, while IPCALAB trades at 33.9, making it slightly expensive compared to peers.
- 🌐 Pharmaceutical sector remains resilient with steady demand.
✅ Conclusion
IPCALAB is a moderately strong swing trade candidate with stable fundamentals and mild bullish technical signals. Entry near ₹1,520–₹1,540 offers a favorable risk-reward setup, with exit around ₹1,620–₹1,640. While valuations are slightly high and profits have dipped, low debt and institutional support make it a reasonable swing trade opportunity.
Would you like me to expand this by adding a peer comparison with Sun Pharma or a pharma sector outlook to provide more context for IPCALAB’s positioning?